Example searches

DNLI Denali Therapeutics, Inc.

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Company profile

Ticker
DNLI
Exchange
NASDAQ
Website
www.denalitherapeutics.com
CEO
Ryan J. Watts
Employees
Incorporated in
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Health Technology > Biotechnology
Industry (SEC)
Biological Products, (No Diagnostic Substances)
Amgen • Gilead Sciences • Biogen • Qiagen • Bio-Techne • Moderna • Acorda Therapeutics • PDL BioPharma • BioNTech SE • bluebird bio ...
SEC CIK
0001714899
Corporate docs

DNLI stock data

(
)
FINRA relative short interest over last month (20 trading days) ?

Calendar

6 Nov 19
19 Feb 20
31 Dec 20

News

Company financial data Financial data

Chart DNLI financial data
Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 13.6M 4.2M 4.21M 125.68M
Net income -46.26M -58.34M -38.99M 77.53M
Diluted EPS -0.48 -0.61 -0.41 0.79
Net profit margin -340% -1390% -927% 61.69%
Operating income -50.16M -62.76M -42.51M 74.72M
Net change in cash 19.74M 23.28M -37.46M 33.47M
Cash on hand 82.67M 62.94M 39.66M 77.12M
Annual (USD) Dec 18 Dec 17 Dec 16
Revenue 129.16M NaN NaN
Net income -36.24M -88.19M -86.65M
Diluted EPS -0.39 -5.89 -13.49
Net profit margin -28.06% NaN% NaN%
Operating income -46.37M -90.14M -87.43M
Net change in cash -141.25M 178.52M
Cash on hand 77.12M 218.38M 39.85M

Financial data from company earnings reports

Institutional ownership Q3 2019

DNLI institutional ownership history Ownership history
73.6% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 116 113 +2.7%
Opened positions 17 23 -26.1%
Closed positions 14 23 -39.1%
Increased positions 37 41 -9.8%
Reduced positions 23 23 –
13F shares
 Current Prev Q Change
Total value 11.03B 1.47B +650.4%
Total shares 70.67M 70.81M -0.2%
Total puts 98.36K 15.8K +522.6%
Total calls 55.42K 50.6K +9.5%
Total put/call ratio 1.8 0.3 +468.5%
Largest owners
 Shares Value Change
Crestline Management 19.46M $298.17M 0.0%
Flagship Pioneering 8.01M $122.65M 0.0%
Baillie Gifford & Co 7.36M $112.81M -0.6%
Vanguard 6.1M $93.41M +4.9%
BLK BlackRock 5.25M $80.38M +1.8%
FMR 4.91M $75.22M -2.7%
Temasek 4.41M $67.57M 0.0%
STT State Street 1.59M $24.39M -19.8%
Lord, Abbett & Co. 1.17M $17.92M -33.0%
Bamco 984.66K $15.09M 0.0%
Largest transactions
 Shares Bought/sold Change
Lord, Abbett & Co. 1.17M -576.04K -33.0%
STT State Street 1.59M -393.93K -19.8%
Vanguard 6.1M +286.13K +4.9%
Casdin Capital 650K +250K +62.5%
Dimensional Fund Advisors 398.32K +193.78K +94.7%
FMR 4.91M -137.62K -2.7%
Balyasny Asset Management 0 -120.4K EXIT
BK Bank Of New York Mellon 338.92K +111.9K +49.3%
Citadel Advisors 88.41K -106.47K -54.6%
FHI Federated Hermes 0 -103.76K EXIT
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Eisai • Mallinckrodt • Biogen • AstraZeneca • Roche • Shire • Cytokinetics • Sanofi • AbbVie • Prothena
Risks
  • Risks Related to Our Business, Financial Condition and Capital Requirements
  • Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
  • Risks Related to Regulatory Approval and Other Legal Compliance Matters
  • Risks Related to Our Reliance on Third Parties
Management Discussion
  • *  Percentage is not meaningful.
  • *  Percentage is not meaningful.
  • Collaboration Revenue. Collaboration revenue was $13.6 million and $22.0 million for the three and nine months ended September 30, 2019, respectively, and $1.2 million and $3.5 million for the three and nine months ended September 30, 2018, respectively. 
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: biomarker, clarification, Japan, NaN, Pronouncement, slightly, website
Removed: assured, confirmed
From filing 10-Q 2019 Q3

Financial reports

View all
10-Q
2019 Q3
Quarterly report
6 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
12 Mar 19
10-Q/A
2018 Q2
Quarterly report (amended)
6 Dec 18
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-K/A
2017 FY
Annual report (amended)
13 Jul 18
10-Q
2018 Q1
Quarterly report
11 May 18
10-K
2017 FY
Annual report
19 Mar 18

Current reports

View all
8-K
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
29 Jan 20
8-K
Denali Therapeutics Announces Proposed Offering of Common Stock
27 Jan 20
8-K
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results from Its LRRK2 Program for Parkinson’s Disease
14 Jan 20
8-K
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
6 Nov 19
8-K
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
6 Aug 19
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 19
8-K
Denali Therapeutics Reports First Quarter 2019 Financial Results
8 May 19
8-K
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
12 Mar 19
8-K
Other Events
4 Jan 19
8-K
Other Events
19 Nov 18

Registration and prospectus

View all
424B5
Prospectus supplement for primary offering
29 Jan 20
424B5
Prospectus supplement for primary offering
27 Jan 20
S-3ASR
Automatic shelf registration
13 Mar 19
S-8
Registration of securities for employees
13 Mar 19
424B4
Prospectus supplement with pricing info
8 Dec 17
S-8
Registration of securities for employees
8 Dec 17
S-1/A
IPO registration (amended)
7 Dec 17
8-A12B
Registration of securities on exchange
30 Nov 17
S-1/A
IPO registration (amended)
27 Nov 17
S-1
IPO registration
13 Nov 17

Proxies

DEFA14A
Additional proxy soliciting materials
18 Apr 19
DEF 14A
Definitive proxy
18 Apr 19
DEFA14A
Additional proxy soliciting materials
26 Apr 18
DEF 14A
Definitive proxy
26 Apr 18

Other

View all
UPLOAD
Letter from SEC
7 Oct 19
CT ORDER
Confidential treatment order
25 Mar 19
CT ORDER
Confidential treatment order
21 Feb 19
CT ORDER
Confidential treatment order
19 Nov 18
CT ORDER
Confidential treatment order
17 Jul 18
CT ORDER
Confidential treatment order
8 Dec 17
EFFECT
Notice of effectiveness
7 Dec 17
CORRESP
Correspondence with SEC
4 Dec 17
CORRESP
Correspondence with SEC
4 Dec 17
CORRESP
Correspondence with SEC
27 Nov 17

Ownership

View all
SC 13G/A
Denali Therapeutics Inc.
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
11 Feb 20
SC 13G/A
Beneficial ownership report (amended)
10 Feb 20
SC 13G/A
Denali Therapeutics Inc.
7 Feb 20
SC 13G
Beneficial ownership report
7 Feb 20
SC 13G/A
Denali Therapeutics Inc.
16 Jan 20
SC 13G/A
Denali Therapeutics Inc.
13 Feb 19
SC 13G
Denali Therapeutics Inc.
11 Feb 19

Patents

GRANT
Utility
Engineered polypeptides
29 Oct 19
Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB.
APP
Utility
Polymorphs and Solid Forms of a Pyrimidinylamino-pyrazole Compound, and Methods of Production
17 Oct 19
The present disclosure relates to crystalline polymorph and amorphous forms of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-1H-pyrazol-1-yl)propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts or cocrystals thereof, and processes for their preparation.
APP
Utility
Compounds, Compositions and Methods
3 Oct 19
The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.